SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine.

Comirnaty® COVID-19 vaccine SARS-CoV-2 SARS-CoV-2-S T cells SARS-CoV-2-S antibodies nursing home residents

Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
06 2022
Historique:
received: 14 02 2022
accepted: 27 02 2022
pubmed: 5 3 2022
medline: 26 5 2022
entrez: 4 3 2022
Statut: ppublish

Résumé

Burgos JS (General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain); Meneu de Guillerna R (Vice-President Foundation Research Institute in Public Services, Valencia, Spain); Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Felipe Research Center-CIPF-, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez-Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); González-Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain); Ferrer Albiach C (Fundación Hospital Provincial de Castelló); Hernández-Aguado I (University Miguel Hernández, Alicante, Spain); Oliver Ramírez N (DataPop Alliance); Sánchez-Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; Vento Torres M (Instituto de Investigación Sanitaria La Fe); Zapater Latorre E (Fundación Hospital General Universitario de València); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain;Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain).

Identifiants

pubmed: 35245583
pii: S0163-4453(22)00124-4
doi: 10.1016/j.jinf.2022.02.035
pmc: PMC8889892
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

834-872

Informations de copyright

Copyright © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Références

J Clin Virol. 2021 Apr;137:104784
pubmed: 33711693
J Infect. 2022 Mar;84(3):418-467
pubmed: 34740744
Allergy. 2022 Jan;77(1):271-281
pubmed: 34286856
Clin Microbiol Infect. 2021 Nov;27(11):1672-1677
pubmed: 34174397
J Infect Dis. 2021 Nov 22;224(10):1690-1693
pubmed: 34514509
Clin Microbiol Infect. 2022 Feb;28(2):279-284
pubmed: 34619398
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
J Infect. 2021 Nov;83(5):559-564
pubmed: 34437927
J Am Geriatr Soc. 2021 Jun;69(6):1441-1447
pubmed: 33768521

Auteurs

Estela Giménez (E)

Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.

Eliseo Albert (E)

Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.

Javier S Burgos (JS)

General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain.

Salvador Peiró (S)

Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.

Dolores Salas (D)

Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain; General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.

Hermelinda Vanaclocha (H)

General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.

Ramón Limón (R)

General Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain.

María Jesús Alcaraz (MJ)

Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.

José Sánchez-Payá (J)

Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain.

Javier Díez-Domingo (J)

Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.

Iñaki Comas (I)

Biomedicine Institute of Valencia, Spanish Research Council (CSIC).

Fernando Gonzáles-Candelas (F)

CIBER in Epidemiology and Public Health, Spain, Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain.
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH